Patents Examined by Jared Barsky
  • Patent number: 10328077
    Abstract: Methods are provided for the treatment of relapsed and/or refractory solid tumors (including neuroendocrine carcinomas (NEC)) and non-Hodgkin's lymphomas (NHLs) and the like, using substituted heterocyclic derivative compounds and pharmaceutical compositions comprising compounds useful for the inhibition of lysine specific demethylase-1 (LSD-1).
    Type: Grant
    Filed: August 9, 2017
    Date of Patent: June 25, 2019
    Assignee: Celgene Corporation
    Inventors: Jiangchun Xu, Robert Cho, Aaron Nguyen
  • Patent number: 10308585
    Abstract: Polymerization inhibitor compositions are provided. The polymerization inhibitor compositions may include at least one hydroxylamine of a nitroxide and at least one phenylenediamine. Methods of inhibiting the unwanted polymerization of monomers are also provided. The methods include adding the presently disclosed polymerization inhibitor compositions to a fluid containing the monomers. The monomers may be ethylenically unsaturated monomers, such as acrylic acid, methacrylic acid, acrylonitrile, methacrylonitrile, acrolein, methacrolein, acrylate, methacrylate, acrylamide, methacrylamide, vinyl acetate, butadiene, ethylene, propylene, and styrene.
    Type: Grant
    Filed: September 27, 2018
    Date of Patent: June 4, 2019
    Assignee: ECOLAB USA INC.
    Inventor: David Youdong Tong
  • Patent number: 10265288
    Abstract: The invention features methods of treating a proliferative disorder characterized by elevated Pin1 marker levels and/or reduced Pin1 Ser71 phosphorylation in a subject by administering a retinoic acid compound. Additionally, the invention features methods of treating proliferative disorders (e.g., proliferative disorders characterized by elevated Pin1 marker levels) by administering a retinoic acid compound in combination with another anti-proliferative compound. Finally, the invention also features methods including high-throughput screens for discovering and validating Pin1 inhibitors.
    Type: Grant
    Filed: July 17, 2014
    Date of Patent: April 23, 2019
    Assignee: Beth Israel Deaconess Medical Center, Inc.
    Inventors: Kun Ping Lu, Shuo Wei, Xiao Zhen Zhou
  • Patent number: 10251961
    Abstract: Novel cromolyn analogs useful as imaging agents for detecting atherosclerotic plaques and for treating atherosclerosis and Alzheimer's Disease, and methods of making the cromolyn analogs, are disclosed. The cromolyn analogs have the general formula: wherein: X is OH, C1-C6 alkoxyl; Y and Z are independently selected form a C1-C6 alkyl, C1-C6 alkoxyl, halogen, un-substituted or C1-C6 substituted amine, 18F, 19F, or H; and n is 1, 2, or 3; and wherein for structure (I), if n are both 1 and Y and Z are both H and X is OH.
    Type: Grant
    Filed: March 9, 2018
    Date of Patent: April 9, 2019
    Assignee: The General Hospital Corporation
    Inventor: David R. Elmaleh
  • Patent number: 10251879
    Abstract: Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.
    Type: Grant
    Filed: March 22, 2018
    Date of Patent: April 9, 2019
    Assignee: ANTECIP BIOVENTURES II LLC
    Inventor: Herriot Tabuteau
  • Patent number: 10245331
    Abstract: Novel cromolyn analogs useful as imaging agents for detecting atherosclerotic plaques and for treating atherosclerosis and Alzheimer's Disease, and methods of making the cromolyn analogs, are disclosed. The cromolyn analogs have the general formula: wherein: X is OH, C1-C6 alkoxyl; Y and Z are independently selected form a C1-C6 alkyl, C1-C6 alkoxyl, halogen, un-substituted or C1-C6 substituted amine, 18F, 19F, or H; and n is 1, 2, or 3; and wherein for structure (I), if n are both 1 and Y and Z are both H and X is OH.
    Type: Grant
    Filed: February 20, 2018
    Date of Patent: April 2, 2019
    Assignee: The General Hospital Corporation
    Inventor: David R. Elmaleh
  • Patent number: 10233185
    Abstract: Compounds represented by general formula (I) (all of the symbols in the formula conform to the definitions in the Description) are compounds that, in addition to having a Btk-selective inhibitory activity, exhibit an excellent metabolic stability and can avoid hepatotoxicity or the like, and as a consequence can provide safe therapeutic agents for diseases in which B cells or mast cells participate.
    Type: Grant
    Filed: February 13, 2018
    Date of Patent: March 19, 2019
    Assignee: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Shingo Yamamoto, Toshio Yoshizawa
  • Patent number: 10226450
    Abstract: The present invention relates to Film Compositions of Ondansetron or its pharmaceutically acceptable salt thereof, which dosage forms are useful for the treatment of various medical conditions.
    Type: Grant
    Filed: November 7, 2014
    Date of Patent: March 12, 2019
    Assignee: SHILPA MEDICARE LIMITED
    Inventors: Navneet Mundada, Ritesh Vinod Birla, Badrinath Allampalli, Akshay Kant Chaturvedi
  • Patent number: 10213418
    Abstract: Uses of pharmaceutical compositions comprising berberine for treatment of dermatologic toxicities and other skin disorders.
    Type: Grant
    Filed: August 21, 2017
    Date of Patent: February 26, 2019
    Assignee: TWi Biotechnology, Inc.
    Inventors: Po-Yuan Tseng, Carol Oscar Brown, III, I-Yin Lin, Chen-En Tsai, Chih-Kuang Chen
  • Patent number: 10206932
    Abstract: Pharmaceutical compositions for co-administering estradiol and progesterone to a human subject in need thereof are provided. In some embodiments, the pharmaceutical composition comprises solubilized estradiol, suspended progesterone, and a solubilizing agent comprising a medium chain (C6-C12) oil.
    Type: Grant
    Filed: May 22, 2015
    Date of Patent: February 19, 2019
    Assignee: TherapeuticsMD, Inc.
    Inventors: Brian A. Bernick, Peter H. R. Persicaner, Julia M. Amadio
  • Patent number: 10206901
    Abstract: A nasal spray composition and method for treating convulsive seizures, including epileptic seizures, and also autism behavioral events. In embodiments, the nasal spray composition contains delta-9-tetrahydrocannabinol and, optionally, terpenes such as linalool.
    Type: Grant
    Filed: September 20, 2017
    Date of Patent: February 19, 2019
    Assignee: JC Pharma, Inc.
    Inventors: Jason Allen Cranford, Donald Channing Cooper
  • Patent number: 10202394
    Abstract: The present disclosure relates to processes for preparing (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide, solid state forms thereof, and corresponding pharmaceutical compositions, methods of treatment (including treatment of rheumatoid arthritis), kits, methods of synthesis, and products-by-process.
    Type: Grant
    Filed: April 4, 2018
    Date of Patent: February 12, 2019
    Assignee: AbbVie Inc.
    Inventors: Jayanthy Jayanth, Patrick J. Marroum, Peter T. Mayer, Mohamed-Eslam F. Mohamed, Ahmed A. Othman, Ben Klünder
  • Patent number: 10202393
    Abstract: The present disclosure relates to processes for preparing (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide, solid state forms thereof, and corresponding pharmaceutical compositions, methods of treatment (including treatment of rheumatoid arthritis), kits, methods of synthesis, and products-by-process.
    Type: Grant
    Filed: April 4, 2018
    Date of Patent: February 12, 2019
    Assignee: AbbVie Inc.
    Inventors: Jayanthy Jayanth, Patrick J. Marroum, Peter T. Mayer, Mohamed-Eslam F. Mohamed, Ahmed A. Othman, Ben Klünder
  • Patent number: 10195178
    Abstract: Disclosed are compositions comprising (a) a GPR40 agonist and (b) an SGLT2 inhibitor, and methods for treating of disorders that are affected by the modulation of the GPR40 receptor and SGLT2 transporter. Such GPR40 compounds are represented by Formula (I) as follows: wherein ring W, R1, R2, R3, R5, R6, A, and Z, are defined herein.
    Type: Grant
    Filed: April 7, 2017
    Date of Patent: February 5, 2019
    Assignee: Janssen Pharmaceutica NV
    Inventors: Yin Liang, Keith T. Demarest
  • Patent number: 10188682
    Abstract: The present invention relates to the use of a compound which inhibits the activity of MKK4 as a medicament for the treatment of a patient suffering from an impaired liver function, to the use of a compound as a medicament for the treatment of liver failure, including acute/fulminant or chronic liver failure and/or for increasing the regeneration of liver tissue in a patient.
    Type: Grant
    Filed: October 6, 2015
    Date of Patent: January 29, 2019
    Assignees: HELMHOLTZ-ZENTRUM FÜR INFEKTIONSFORSCHUNG GMBH, MEDIZINISCHE HOCHSCHULE HANNOVER
    Inventors: Lars Zender, Torsten Wuestefeld
  • Patent number: 10188757
    Abstract: Novel cromolyn analogs useful as imaging agents for detecting atherosclerotic plaques and for treating atherosclerosis and Alzheimer's Disease, and methods of making the cromolyn analogs, are disclosed. The cromolyn analogs have the general formula; wherein X is OH, C1-C6 alkoxyl; Y and Z are independently selected from a C1-C6 alkyl, C1-C6 alkoxyl, halogen, mi-substituted or C1-C6 substituted amine, 18F, 19F, or H; and n is 1, 2, or 3; and wherein for structure (I), if n are both 1 and Y and Z are both H and X is OH.
    Type: Grant
    Filed: October 22, 2014
    Date of Patent: January 29, 2019
    Assignee: The General Hospital Corporation
    Inventor: David R. Elmaleh
  • Patent number: 10172862
    Abstract: Imipridones selectively modulate Class A G protein-coupled receptors (GPCRs), such as the D2-like subfamily of dopamine receptors, and are useful for treating conditions and disorders in need of such modulation, such as cancers. Specifically, the cancer is a midline glioma, a cancer having a histone H3 mutation, or both. In addition, methods of identifying whether a subject having these conditions, is likely to be responsive to a treatment regimen, such as imipridone administration, are provided. Furthermore, methods of assessing the effectiveness of a treatment regimen, such as imipridone administration, monitoring, or providing a prognosis for a subject with these condition are also provided.
    Type: Grant
    Filed: April 8, 2018
    Date of Patent: January 8, 2019
    Assignee: Oncoceutics, Inc.
    Inventors: Joshua E. Allen, Martin Stogniew, Varun Vijay Prabhu
  • Patent number: 10174073
    Abstract: The present invention relates to obeticholic acid: or a pharmaceutically acceptable salt, solvate or amino acid conjugate thereof. Obeticholic acid is useful for the treatment or prevention of a FXR mediated disease or condition, cardiovascular disease or cholestatic liver disease, and for reducing HDL cholesterol, for lowering triglycerides in a mammal, or for inhibition of fibrosis. The present invention also relates to processes for the synthesis of obeticholic acid.
    Type: Grant
    Filed: April 25, 2017
    Date of Patent: January 8, 2019
    Assignee: Intercept Pharmaceuticals, Inc.
    Inventors: André Steiner, Heidi Waenerlund Poulsen, Emilie Jolibois, Melissa Rewolinski, Ralf Gross, Emma Sharp, Fiona Dubas-Fisher, Alex Eberlin
  • Patent number: 10173986
    Abstract: Methods for the safe administration of imidazole or imidazolium compounds such as zoledronic acid, and conditions that may be treated by these methods, are described herein.
    Type: Grant
    Filed: May 25, 2017
    Date of Patent: January 8, 2019
    Assignee: ANTECIP BIOVENTURES II LLC
    Inventor: Herriot Tabuteau
  • Patent number: 10155787
    Abstract: The present invention relates to obeticholic acid: or a pharmaceutically acceptable salt, solvate or amino acid conjugate thereof. Obeticholic acid is useful for the treatment or prevention of a FXR mediated disease or condition, cardiovascular disease or cholestatic liver disease, and for reducing HDL cholesterol, for lowering triglycerides in a mammal, or for inhibition of fibrosis. The present invention also relates to processes for the synthesis of obeticholic acid.
    Type: Grant
    Filed: November 20, 2015
    Date of Patent: December 18, 2018
    Assignee: Intercept Pharmaceuticals, Inc.
    Inventors: André Steiner, Heidi Waenerlund Poulsen, Emilie Jolibois, Melissa Rewolinski, Ralf Gross, Emma Sharp, Fiona Dubas-Fisher, Alex Eberlin